Item 5.07. Submission of Matters to a Vote of Security Holders.
On
The Company had 13,667,973 shares of common stock and one share of Series D
preferred stock (the "Preferred Stock") issued and outstanding at the close of
business on
As previously described in in the Company's Proxy Statement, the holder of record of the one outstanding share of Preferred Stock was entitled to 17,500,000 votes, had the right to vote only on the Reverse Stock Split Proposal, and such votes were automatically voted in the same proportion as the shares of common stock voted on the Reverse Stock Proposal. Holders of the Company's common stock were entitled to one vote per share.
The Reverse Stock Split Proposal submitted to a vote of the Company's stockholders at the Special Meeting was approved. The ratio and effective date of the reverse stock split will be reported on a separate Current Report on Form 8-K once approved by the Company's Board of Directors.
At the Special Meeting, the Company's stockholders voted in the following manner with respect to the Reverse Stock Split Proposal:
For Against Abstain 19,728,800 4,120,599 150,982
Item 7.01. Regulation FD Disclosure.
On
The information furnished under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Number Description 99.1Phio Pharmaceuticals Corp. Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
© Edgar Online, source